TETmedical, Inc.
TETmedical, Inc. is a clinical-stage nanomedicine company specializing in advanced in vitro diagnostic platforms for acute and high-consequence diseases. Originating from research at Cornell University, the company leverages tethered enzyme technologies on nanoparticles to create rapid, sensitive, and robust molecular machines for detection of biomarkers. Their lead product is a rapid functional assay for stroke diagnosis, and their pipeline includes technologies for infectious disease detection and at-home liver function testing.
Industries
N/A
Nr. of Employees
small (1-50)
TETmedical, Inc. is currently seeking investment
TETmedical, Inc. is seeking a series-a investment in the range of 5m-20m
Patents
Apparatus and methods using tethered enzymes for the detection of the enzymatic activity of biomarkers
2025-05-20 • US-12306187-B2
View Details
Apparatus and methods using tethered enzymes for the detection of the enzymatic activity of biomarkers
2025-05-20 • US-12306187-B2
View DetailsProducts
In vitro diagnostic blood test detecting acute brain injury from stroke by measuring neuron-specific enolase enzymatic activity using a rapid, signal-amplified, nanoparticle enzyme platform. Compatible with standard plate readers; designed for application in Emergency Departments.
In vitro diagnostic blood test detecting acute brain injury from stroke by measuring neuron-specific enolase enzymatic activity using a rapid, signal-amplified, nanoparticle enzyme platform. Compatible with standard plate readers; designed for application in Emergency Departments.
Expertise Areas
- Nanoengineered diagnostics
- Enzyme-based biosensors
- Clinical validation of in vitro diagnostics
- Rapid acute disease diagnostics
Key Technologies
- Enzyme tethering on nanoparticles
- Catalytic signal amplification
- Activity-based biomarker detection
- Luminescence-based assay readout
Key People
David Fischell, PhD
CEO and Co-Founder
Alex Travis, VMD, PhD
Director and Co-Founder, Cornell Professor
Roy Cohen, PhD
Director, Co-Inventor, Co-Founder, Cornell Assistant Research Professor
Christine Bunt
Director, Managing Director at BuntAssociates LLC
Hooman Kamel, MD
Senior Medical Advisor
John Conley
Director, Launchpad Ventures Representative
David Fischell, PhD
CEO and Co-Founder
Alex Travis, VMD, PhD
Director and Co-Founder, Cornell Professor
Roy Cohen, PhD
Director, Co-Inventor, Co-Founder, Cornell Assistant Research Professor
Christine Bunt
Director, Managing Director at BuntAssociates LLC
Hooman Kamel, MD
Senior Medical Advisor
John Conley
Director, Launchpad Ventures Representative
News & Updates
Research article analyzing how nanoparticle size influences the formation and reaction kinetics of multilayered tethered enzyme systems.
Study describing a bio-inspired approach that enables efficient, multi-step enzymatic reactions when enzymes are tethered on nanoparticles.
Demonstrates the application of tethered enzyme systems as rapid-response platforms for analyte detection.
Methods for enhanced monitoring of brain injury using enzyme activity-based biosensors measuring neuron-specific enolase.
Demonstrates that biomimetic tethering increases the efficiency of sequential glycolytic enzyme reactions.
Explores the evolving roles and applications of microRNA in diagnostics and therapeutics.
Research article analyzing how nanoparticle size influences the formation and reaction kinetics of multilayered tethered enzyme systems.
Study describing a bio-inspired approach that enables efficient, multi-step enzymatic reactions when enzymes are tethered on nanoparticles.
Demonstrates the application of tethered enzyme systems as rapid-response platforms for analyte detection.
Methods for enhanced monitoring of brain injury using enzyme activity-based biosensors measuring neuron-specific enolase.
Demonstrates that biomimetic tethering increases the efficiency of sequential glycolytic enzyme reactions.
Explores the evolving roles and applications of microRNA in diagnostics and therapeutics.